Androgen deficiency

Androgenic deficiency in male rats given a single oral dose of 15 pg 2,3,7,8-TCDD/kg BW was evident as early as 2 days posttreatment, with persistence up to 12 days. These deficiencies may account for male reproductive pathology and dysfunction in rats treated with overtly toxic doses of TCDD. Findings included depression in plasma testosterone concentrations, as well as decreased weight of seminal vesicles (by 68%), ventral prostate gland (by 48%), testes, and epididymis (Moore et al. 1985). 

Moore, R.W., C.L. Potter, H.M. Theobald, J.A. Robinson, and R.E. Peterson. 1985. Androgenic deficiency in male rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 79 99-111. 

Androgens are used for therapy of androgen-deficient conditions such as hypofunctioning testicles, eunuchism and eunuchoidism, castration, impotence, climacteric conditions, and also for breast and ovarian cancer in women under 60 years. 

Replacement therapy Replacement therapy in androgen-deficient males is 10 to 50 mg of methyltestosterone daily. 

Anawalt BD. T in cheek buccal testosterone as a new treatment for androgen deficiency in men. In US endocrine disease 2006. Available from URL http // www.touchbriefings.com/cdps/cditem.cfm NID=1815 [cited 2008 Jan 05]. 

Mechanism of Action A synthetic testosterone derivative with androgen activity that promotes growth and development of male sex organs and maintains secondary sex characteristics in androgen-deficient males, TIicrapcuticE/fcct Treats hypogonadism in males. 

Mechanism of Action A synthetic testosterone derivative that promotes growth and development of male sex organs, maintains secondary sex characteristics in androgen-deficient males. Therapeutic Effect Androgenic and anabolic actions. Pharmacokinetics Well absorbed from fhe gastrointestinal (GI) tract. Protein binding 94%-97%. Metabolized in liver. Primarily excreted in urine. Unknown if removed by hemodialysis. Half-life 5-13 hr. 

Anonymous. Treatment of androgen deficiency in the aging male. Fertil Steril 2004 81 1437 10. 

Testosterone is used to treat various androgen deficiency syndromes. Following oral administration, free testosterone is effectively metabolized and inactivated in the liver before it reaches the systemic circulation [65], and unless very high doses are administered, no testosterone is detected in the plasma [66]. Testosterone undecanoate is a prodrug of testosterone esterified in the 17 3-position with undecanoic acid. Following oral administration, this prodrug is metabolized only partly in the intestinal wall [67], and the remaining fraction of... 

Generic Name Fluoxymesterone Trade Name(s) Android-F, Halotestin Primary Indication(s) Androgen deficiency breast cancer in women delayed puberty in boys anemia Routes of Administration Oral... 

Testosterone injectable suspension Testamone, Testaqua Androgen deficiency breast cancer delayed puberty in boys Intramuscular... 

Testosterone implants Testopel pellets Androgen deficiency delayed puberty in boys Subcutaneous... 

Testosterone gel Testoderm, Andro-derm Androgen deficiency Transdermal... 

Moore RW, Potter CL, Theobald HM, et al. 1985. Androgenic deficiency in male rats treated with... 

Evaporative dysfunction is caused by a reduction in the lipid layer of the tear film. Most often, this condition is caused by MGD or blepharitis. MGD is traditionally conceptualized as a triad of meibomianitis (stagnated secretions within the meibomian glands), meibomian seborrhea (overabundance of meibomian secretions into the tear film), and seborrheic blepharitis (oily debris visible on the eyelashes and ocular adnexal surfeces). Additionally, we have become increasingly aware of the influence of male hormones, or androgens, on the health of the meibomian glands. Clinically significant androgen deficiency, which naturally occurs in women of menopausal age and men in... 

Sullivan D, Belanger A, Cermak J, et al. Are women with Sjogren s syndrome androgen-deficient J Rheumatol 2003 30 2413-2419. 

Sullivan D, SuUivan B, Evans J, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002 966 211-222. 

Ruoxymesterone, USP. Fluoxyme.sterone, 9cr-f1uoro-11/3,17 ihydroxy-17-methylandrost-4-cn-3-one, is a hi ly potent, orally active androgen, about 5 to 10 times mare potent than testosterone. It can be used for all the indications di.scussed above, but its great androgenic activity has made it useful primarily for treatment of the androgen-deficient male. 

Demers LM. Andropause an androgen deficiency state in the ageing male. Expert Opin Pharmacother 2003 4 183-90. 

---